Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

TQD3524

Phase 2Small molecule

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

1

Indications

2

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hospital-Acquired Bacterial Pneumonia/ventilator-Associated Bacterial PneumoniaRecruiting

Hospital-Acquired Bacterial Pneumonia/ventilator-Associated Bacterial PneumoniaPhase 2

Recruiting

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

Hospital-Acquired Bacterial Pneumonia/ventilator-Associated Bacterial Pneumonia

NCT07512596

Clinical

Trials by Indication[1]

Renal Impairment1 trial

To Evaluate the Pharmacokinetics and Safety of TQD3524 for Injection in Renal Impairment Subjects

Completed· Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 1·NCT06522945·48 enrolled

Hospital-acquired Bacterial Pneumonia/Ventilator-associated Bacterial Pneumonia1 trial

Randomized, Double-blind, Parallel-controlled, Multicenter Phase II Clinical Study to Evaluate the Efficacy and Safety of Polymyxin E2 Mesylate Intravenous Infusion Combined With Nebulized Inhalation in the Treatment of Hospital-acquired Bacterial Pneumonia/Ventilator-associated Bacterial Pneumonia Caused by Carbapenem-resistant Gram-negative Bacteria

Recruiting· Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 2·NCT07512596·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for TQD3524. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TQD3524 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TQD3524. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Chia Tai Tianqing Pharmaceutical Group Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Related News